{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:39:36Z","timestamp":1794440376321,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770213"],"award-info":[{"award-number":["81770213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["19JCYBJC26500"],"award-info":[{"award-number":["19JCYBJC26500"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-XD2019-162, Y-Roche20192-0097"],"award-info":[{"award-number":["Y-XD2019-162, Y-Roche20192-0097"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41375-022-01634-w","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T11:03:16Z","timestamp":1657796596000},"page":"2269-2280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations"],"prefix":"10.1038","volume":"36","author":[{"given":"Yuheng","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-0026","authenticated-orcid":false,"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7663-2923","authenticated-orcid":false,"given":"Xianhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"1634_CR1","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: A Haematological Malignancy Research Network report. Blood 2020;135:1759\u201371.","journal-title":"Blood"},{"key":"1634_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-Cell lymphoma. N Engl J Med. 2021;384:842\u201358.","journal-title":"N Engl J Med"},{"key":"1634_CR3","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"1634_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"1634_CR5","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse Large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551\u201368.e14.","journal-title":"Cancer Cell"},{"key":"1634_CR6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/sj.cdd.4401916","volume":"13","author":"O Laptenko","year":"2006","unstructured":"Laptenko O, Prives C. Transcriptional regulation by p53: One protein, many possibilities. Cell Death Differ. 2006;13:951\u201361.","journal-title":"Cell Death Differ"},{"key":"1634_CR7","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW. Putting p53 in context. Cell 2017;170:1062\u201378.","journal-title":"Cell"},{"key":"1634_CR8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ng.892","volume":"43","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43:830\u20137.","journal-title":"Nat Genet"},{"key":"1634_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc.2017.109","volume":"18","author":"VJN Bykov","year":"2018","unstructured":"Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89\u2013102.","journal-title":"Nat Rev Cancer"},{"key":"1634_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc2693","volume":"9","author":"R Brosh","year":"2009","unstructured":"Brosh R, Rotter V. When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer. 2009;9:701\u201313.","journal-title":"Nat Rev Cancer"},{"key":"1634_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1042\/BST20150261","volume":"44","author":"L Aschauer","year":"2016","unstructured":"Aschauer L, Muller PA. Novel targets and interaction partners of mutant p53 gain-of-function. Biochem Soc Trans. 2016;44:460\u20136.","journal-title":"Biochem Soc Trans"},{"key":"1634_CR12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/ng1091","volume":"33","author":"MT Hemann","year":"2003","unstructured":"Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C, et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet. 2003;33:396\u2013400.","journal-title":"Nat Genet"},{"key":"1634_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm0302-282","volume":"8","author":"VJ Bykov","year":"2002","unstructured":"Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8:282\u20138.","journal-title":"Nat Med"},{"key":"1634_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0463-7","volume":"9","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bykov VJN, Wiman KG, Zawacka-Pankau J. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death Dis. 2018;9:439.","journal-title":"Cell Death Dis"},{"key":"1634_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/15384047.2015.1026482","volume":"16","author":"M Sobhani","year":"2015","unstructured":"Sobhani M, Abdi J, Manujendra SN, Chen C, Chang H. PRIMA-1Met induces apoptosis in Waldenstr\u00f6m\u2019s Macroglobulinemia cells independent of p53. Cancer Biol Ther. 2015;16:799\u2013806.","journal-title":"Cancer Biol Ther"},{"key":"1634_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3324\/haematol.2020.259531","volume":"107","author":"R Birsen","year":"2022","unstructured":"Birsen R, Larrue C, Decroocq J, Johnson N, Guiraud N, Gotanegre M, et al. APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. Haematologica. 2022;107:403\u201316.","journal-title":"Haematologica"},{"key":"1634_CR17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3324\/haematol.2019.218453","volume":"105","author":"N Maslah","year":"2020","unstructured":"Maslah N, Salomao N, Drevon L, Verger E, Partouche N, Ly P, et al. Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. Haematologica 2020;105:1539\u201351.","journal-title":"Haematologica"},{"key":"1634_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.143","volume":"6","author":"N Mohell","year":"2015","unstructured":"Mohell N, Alfredsson J, Fransson \u00c5, Uustalu M, Bystr\u00f6m S, Gullbo J, et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 2015;6:e1794.","journal-title":"Cell Death Dis"},{"key":"1634_CR19","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-10-3168","volume":"17","author":"R Zandi","year":"2011","unstructured":"Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS. PRIMA-1Met\/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res. 2011;17:2830\u201341.","journal-title":"Clin Cancer Res"},{"key":"1634_CR20","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1182\/blood-2014-01-548800","volume":"124","author":"B Tessoulin","year":"2014","unstructured":"Tessoulin B, Descamps G, Moreau P, Ma\u00efga S, Lod\u00e9 L, Godon C, et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH\/ROS balance. Blood 2014;124:1626\u201336.","journal-title":"Blood"},{"key":"1634_CR21","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","volume":"30","author":"S Lehmann","year":"2012","unstructured":"Lehmann S, Bykov VJ, Ali D, Andr\u00e9n O, Cherif H, Tidefelt U, et al. Targeting p53 in vivo: A first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012;30:3633\u20139.","journal-title":"J Clin Oncol"},{"key":"1634_CR22","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021;39:1584\u201394.","journal-title":"J Clin Oncol"},{"key":"1634_CR23","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","volume":"23","author":"S Dubois","year":"2017","unstructured":"Dubois S, Viailly PJ, Bohers E, Bertrand P, Ruminy P, Marchand V, et al. Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-Cell lymphoma: Analysis of 361 cases. Clin Cancer Res. 2017;23:2232\u201344.","journal-title":"Clin Cancer Res"},{"key":"1634_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.18.01314","volume":"37","author":"C Sha","year":"2019","unstructured":"Sha C, Barrans S, Cucco F, Bentley MA, Care MA, Cummin T, et al. Molecular high-grade B-Cell lymphoma: Defining a poor-risk group that requires different approaches to therapy. J Clin Oncol. 2019;37:202\u201312.","journal-title":"J Clin Oncol"},{"key":"1634_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell 2017;171:481\u201394.e15.","journal-title":"Cell"},{"key":"1634_CR26","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1182\/blood-2008-01-129783","volume":"112","author":"KH Young","year":"2008","unstructured":"Young KH, Leroy K, M\u00f8ller MB, Colleoni GW, S\u00e1nchez-Beato M, Kerbauy FR, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008;112:3088\u201398.","journal-title":"Blood"},{"key":"1634_CR27","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","volume":"16","author":"Y Miao","year":"2019","unstructured":"Miao Y, Medeiros LJ, Li Y, Li J, Young KH. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16:634\u201352.","journal-title":"Nat Rev Clin Oncol"},{"key":"1634_CR28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","volume":"20","author":"M Challa-Malladi","year":"2011","unstructured":"Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV, et al. Combined genetic inactivation of \u03b22-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011;20:728\u201340.","journal-title":"Cancer Cell"},{"key":"1634_CR29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2015.158","volume":"23","author":"Y Xie","year":"2016","unstructured":"Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. Ferroptosis: Process and function. Cell Death Differ. 2016;23:369\u201379.","journal-title":"Cell Death Differ"},{"key":"1634_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","volume":"148","author":"L Sun","year":"2012","unstructured":"Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012;148:213\u201327.","journal-title":"Cell"},{"key":"1634_CR31","doi-asserted-by":"publisher","first-page":"eaat2738","DOI":"10.1126\/sciimmunol.aat2738","volume":"3","author":"JK Rathkey","year":"2018","unstructured":"Rathkey JK, Zhao J, Liu Z, Chen Y, Yang J, Kondolf HC, et al. Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. Sci Immunol. 2018;3:eaat2738.","journal-title":"Sci Immunol"},{"key":"1634_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","volume":"12","author":"DJ Klionsky","year":"2016","unstructured":"Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:1\u2013222.","journal-title":"Autophagy"},{"key":"1634_CR33","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1023\/A:1024116916932","volume":"8","author":"TM Caserta","year":"2003","unstructured":"Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 2003;8:345\u201352.","journal-title":"Apoptosis"},{"key":"1634_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tcb.2015.10.014","volume":"26","author":"WS Yang","year":"2016","unstructured":"Yang WS, Stockwell BR. Ferroptosis: Death by lipid peroxidation. Trends Cell Biol. 2016;26:165\u201376.","journal-title":"Trends Cell Biol"},{"key":"1634_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tibs.2010.07.007","volume":"36","author":"R Scherz-Shouval","year":"2011","unstructured":"Scherz-Shouval R, Elazar Z. Regulation of autophagy by ROS: Physiology and pathology. Trends Biochem Sci. 2011;36:30\u20138.","journal-title":"Trends Biochem Sci"},{"key":"1634_CR36","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"1634_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017;171:273\u201385.","journal-title":"Cell"},{"key":"1634_CR38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pharmthera.2013.09.006","volume":"141","author":"GF Rushworth","year":"2014","unstructured":"Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: The need for conversion to intracellular glutathione for antioxidant benefits. Pharm Ther. 2014;141:150\u20139.","journal-title":"Pharm Ther"},{"key":"1634_CR39","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41418-020-00728-1","volume":"28","author":"X Chen","year":"2021","unstructured":"Chen X, Yu C, Kang R, Kroemer G, Tang D. Cellular degradation systems in ferroptosis. Cell Death Differ. 2021;28:1135\u201348.","journal-title":"Cell Death Differ"},{"key":"1634_CR40","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1016\/j.celrep.2020.02.049","volume":"30","author":"H Feng","year":"2020","unstructured":"Feng H, Schorpp K, Jin J, Yozwiak CE, Hoffstrom BG, Decker AM, et al. Transferrin receptor is a specific ferroptosis marker. Cell Rep. 2020;30:3411\u201323.e7.","journal-title":"Cell Rep"},{"key":"1634_CR41","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41556-019-0305-6","volume":"21","author":"B Chu","year":"2019","unstructured":"Chu B, Kon N, Chen D, Li T, Liu T, Jiang L, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 2019;21:579\u201391.","journal-title":"Nat Cell Biol"},{"key":"1634_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10534-011-9500-z","volume":"25","author":"RJ Hilton","year":"2012","unstructured":"Hilton RJ, David Andros N, Watt RK. The ferroxidase center is essential for ferritin iron loading in the presence of phosphate and minimizes side reactions that form Fe(III)-phosphate colloids. Biometals 2012;25:259\u201373.","journal-title":"Biometals"},{"key":"1634_CR43","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/15548627.2016.1187366","volume":"12","author":"W Hou","year":"2016","unstructured":"Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ 3rd, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 2016;12:1425\u20138.","journal-title":"Autophagy"},{"key":"1634_CR44","doi-asserted-by":"publisher","first-page":"101670","DOI":"10.1016\/j.redox.2020.101670","volume":"36","author":"DC Fuhrmann","year":"2020","unstructured":"Fuhrmann DC, Mondorf A, Beifu\u00df J, Jung M, Br\u00fcne B. Hypoxia inhibits ferritinophagy, increases mitochondrial ferritin, and protects from ferroptosis. Redox Biol. 2020;36:101670.","journal-title":"Redox Biol"},{"key":"1634_CR45","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/cr.2016.95","volume":"26","author":"M Gao","year":"2016","unstructured":"Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26:1021\u201332.","journal-title":"Cell Res"},{"key":"1634_CR46","doi-asserted-by":"publisher","first-page":"e10308","DOI":"10.7554\/eLife.10308","volume":"4","author":"JD Mancias","year":"2015","unstructured":"Mancias JD, Pontano Vaites L, Nissim S, Biancur DE, Kim AJ, Wang X, et al. Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. Elife. 2015;4:e10308.","journal-title":"Elife"},{"key":"1634_CR47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/humu.10190","volume":"21","author":"S Peller","year":"2003","unstructured":"Peller S, Rotter V. TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance. Hum Mutat. 2003;21:277\u201384.","journal-title":"Hum Mutat"},{"key":"1634_CR48","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","volume":"110","author":"KH Young","year":"2007","unstructured":"Young KH, Weisenburger DD, Dave BJ, Smith L, Sanger W, Iqbal J, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 2007;110:4396\u2013405.","journal-title":"Blood"},{"key":"1634_CR49","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1038\/bcj.2016.60","volume":"6","author":"S Deneberg","year":"2016","unstructured":"Deneberg S, Cherif H, Lazarevic V, Andersson PO, von Euler M, Juliusson G. et al. An open-label phase I dose-finding study of APR-246 in hematological malignancies. Blood Cancer J. 2016;6:e447","journal-title":"Blood Cancer J"},{"key":"1634_CR50","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1158\/1535-7163.MCT-12-1166","volume":"12","author":"MN Saha","year":"2013","unstructured":"Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1Met\/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol Cancer Ther. 2013;12:2331\u201341.","journal-title":"Mol Cancer Ther"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01634-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01634-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01634-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T10:04:32Z","timestamp":1661508272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01634-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01634-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"24 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"COMPETING INTERESTS"}}]}}